新科学想法 › 文献管理 › 浏览文献

Antibody pharmacokinetics and pharmacodynamics

cyzhgt 添加于 2011-12-12 10:45 | 1176 次阅读 | 0 个评论

作者
Lobo ED, Hansen RJ, Balthasar JP
摘要
The U.S. Food and Drug administration (FDA) has approved several polyclonal antibody preparations and at least 18 monoclonal antibody preparations (antibodies, antibody fragments, antibody fusion proteins, etc.). These drugs, which may be considered as a diverse group of therapeutic proteins, are associated with several interesting pharmacokinetic characteristics. Saturable binding with target antigen may influence antibody disposition, potentially leading to nonlinear distribution and elimination. Independent of antigen interaction, concentration-dependent elimination may be expected for IgG antibodies, due to the influence of the Brambell receptor, FcRn, which protects IgG from catabolism. Antibody administration may induce the development of an endogenous antibody response, which may alter the pharmacokinetics of the therapeutic antibody. Additionally, the pharmacodynamics of antibodies are also complex; these drugs may be used for a wide array of therapeutic applications, and effects may be achieved by a variety of mechanisms. This article provides an overview of many of the complexities associated with antibody pharmacokinetics and pharmacodynamics.
详细资料
- 文献种类:期刊
- 期刊名称: Journal of Pharmaceutical Sciences
- 期刊缩写: J Pharm Sci
- 期卷页: 2004年第93卷第11期 2645-2668页
- 地址: Global PK/PD and Trial Simulations, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
- ISBN: 0022-3549
- 备注:PMID:15389672
相关链接 DOI URL
cyzhgt 的文献笔记订阅